Catalyst announces vamorolone Phase 1 data showing expected cortisol suppression without significant immunosuppression.
Catalyst Pharmaceuticals reported top-line Phase 1 data for vamorolone demonstrating balanced corticosteroid activity without evidence of immunosuppression. This validates the drug's differentiated safety profile for chronic inflammatory diseases.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day